This activity is expired and is no longer available for CME credit.


Avoiding the Blind Spot: Facts, Figures, and Findings about Myopic Choroidal Neovascularization

Author(s)/Faculty: Rishi P. Singh, MD; K. Bailey Freund, MD; Lawrence S. Morse, MD, PhD
Release Date: 10/3/2017Expiration Date: 9/20/2019
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
Myopic choroidal neovascularization (mCNV) is a rare complication of myopia with a high-risk of long-term vision loss if not differentially diagnosed early and treated promptly. Furthermore, approximately 35% of patients diagnosed with mCNV in one eye will develop mCNV in the other eye within 10 years. Misdiagnosis is common because mCNV shares similar clinical characteristics to age-related macular degeneration resulting in delayed and inappropriate management. Treatment options for mCNV within the United States include verteporfin photodynamic therapy (vPDT), laser photocoagulation, and intravitreal anti-VEGF injections, bevacizumab, aflibercept, and ranibizumab with the latter approved in January 2017 as the first anti-VEGF therapy for mCNV. However, no evidence based guidelines exist for the utilization of anti-VEGF therapies in mCNV resulting in suboptimal treatment and subsequent poor visual outcomes. Within this CME activity, a panel of experts in the field provide discussion and clinical insights for the differential diagnosis of mCNV, review of pertinent clinical trials and their outcomes, as well as guidance for the integration of diagnostic and therapeutic algorithms into everyday practice via clinical case studies.